NYMC > Faculty > Directory > By Name > Guo, Austin

Austin Meng Guo, Ph.D.

Assistant Professor of Pharmacology

Dr. Guo researches the role of Cytochrome P450 derived eicasonoids, specifically 20-hydroxyeicosatetraenoic acid (20-HETE), in the regulation of angiogenesis and cancer growth. Abnormal neovascularization is associated with many serious human diseases, ie. ischemia and cancer. Pharmacological inhibitors of 20-HETE synthases and 20-HETE antagonists have been shown to decrease the growth of some cancers both in vitro and in vivo suggesting the CYP4A/F-20-HETE system may be a novel target for treating some cancers.

Email: Austin_Guo@nymc.edu

Address:

Department of Pharmacology
New York Medical College
15 Dana Rd, Room 546B
Valhalla, NY 10595
Phone: (914) 594-4625
Lab: (914) 594-4720
Fax: (914) 347-4956

Professional Interests:

Our research interests are focused on the role of Cytochrome P450-derived eicosanoids, specifically 20-hydroxyeicosatetraenoic acid (20-HETE), in the regulation of angiogenesis and cancer growth. Abnormal neovascularization is associated with many serious human diseases, i.e., ischemia and cancer. Recent developments in stem cell biology suggest that circulating endothelial precursor cells (EPC) contribute to postnatal neovascularization, which is an important adaptation for recovery from critical ischemia. Since EPC-induced neovascularization appears essential for repair of ischemic tissue, it is crucial that we understand the factors that regulate EPC involvement in the neovascularization process. We have shown that the 20-HETE and its synthases (CYP4A and F family of enzymes in human) regulate EPC angiogenic functions such as proliferation, migration, and angiogenic gene expression. Inhibition of 20-HETE synthesis or antagonizing 20-HETE actions decrease ischemia-induced compensatory neovascularization in vivo. Thus, the CYP4A-20-HETE system may be a key to the regulation of the angiogenic and homing functions of EPC in response to ischemia. Stemming from our studies in the role of the CYP4A/F-20-HETE system in regulation of angiogenic processes, we are also interested in the regulation of cancer growth by the CYP4A/F-20-HETE system. Pharmacological inhibitors of 20-HETE synthases and 20-HETE antagonists have been shown to decrease the growth of some cancers both in vitro and in vivo, suggesting the CYP4A/F-20-HETE system may be a novel target for treating some cancers.

Education Profile:

Graduate Degree: Ph.D.
Graduate Degree Institution: Wayne State University, Detroit, MI, Ph.D. - Cancer Biology, 2001
Saint Cloud State University, St. Cloud, MN B.S. with Honors - Biotechnology, 1995

Selected Bibliography:

  1. Chen, L., Joseph, G., Zhang, F.F., Nguyen, H., Jiang, H., Gotlinger, K.H., Falck, J.R., Yang, J., Schwartzman, M.L., Guo, A.M. 20-HETE Contributes to Ischemia-induced Angiogenesis. Vasc. Pharmacol., (under review), 2015.
  2. Borin, T.F., Zuccari, D.A., Jardim-Perassi, B.V., Ferreira, L.C., Iskander, A.S., Varma, N.R., Shankar, A., Guo, A.M., Scicli, G., Arbab, A.S. HET0016, a Selective Inhibitor of 20-HETE Synthesis, Decreases Pro-Angiogenic Factors and Inhibits Growth of Triple Negative Breast Cancer in Mice. PLoS One, 9: e116247, 2014.
  3. Zheng, H., Li, Y., Wang, Y., Zhao, H., Zhang, J., Chai, H., Tang, T., Yue, J., Guo, A.M., Yang, J. Downregulation of COX-2 and CYP 4A signaling by isoliquiritigenin inhibits human breast cancer metastasis through preventing anoikis resistance, migration and invasion. Toxi. Appl. Pharmacol.280: 10-20, 2014
  4. Zhao, H., Li, Y., Ke, Z., Tang, T., Chai, H., Chen, X., Tang, Y., Chen, H., Guo, A.M., Yang, J. Isoliquiritigenin, a flavonoid from licorice, blocks M2 macrophage polarization in colitis-associated tumorigenesis through downregulating PGE2 and IL-6. Toxi. Appl. Pharmacol.272: 37-48, 2014
  5. Chen, L., Ackerman, R., Gotlinger, K.H., Kessler, M., Mendelowitz, L.G., Falck, J.R., Arbab, S.A., Scilci, A.G., Schwartzman, M.L., Yang, J., Guo, A.M. 20-HETE regulates angiogenic functions of human endothelial progenitor cells and contributes to EPC mediated angiogenesis in vivo.  J. Pharmacol. Exp. Ther., 348: 442-451, 2014.

Search PubMed for all available publications of Austin Meng Guo, Ph.D.